The method triggers immune responses that inhibit melanoma, triple-negative breast cancer, lung carcinoma, and ovarian cancer ...

EVM14 received FDA clearance for clinical trials, marking Everest Medicines’ first in-house developed therapeutic to reach ...

RNA cancer vaccines are at the forefront of next-generation cancer immunotherapy, showcasing significant potential.

The FDA cleared the investigational new drug (IND) application for EVM14. EVM14 is an off-the-shelf tumor-associated antigen ...

EVM14 received U.S. FDA clearance for its IND application, becoming Everest's first internally discovered program, and the first mRNA therapeutic cancer vaccine to be cleared for global clinical ...

John T. Wilson is in the Department of Chemical and Biomolecular Engineering and the Department of Biomedical Engineering at Vanderbilt University, Nashville, Tennessee 37235, USA, and in the ...

Researchers at the Icahn School of Medicine at Mount Sinai, led by Nina Bhardwaj, MD, Ph.D., Ward-Coleman Chair in Cancer ...

What’s Up With mRNA Research? A research nurse holds an injection of a BioNTech mRNA cancer immunotherapy for non-small cell ...

EVM14 received U.S. FDA clearance for its IND application, becoming Everest's first internally discovered program, and the first mRNA therapeutic cancer vaccine to be cleared for global clinical ...

including personalized cancer vaccines (PCVs), tumor-associated antigen (TAA) cancer vaccines, immunomodulatory cancer vaccines, and in vivo CAR-T therapies. Additionally, the Company is working ...